DEA raises eyebrows over marijuana debt restructuring

Terran Cooper, regulatory counsel at Falcon Rappaport & Berkman LLP, a major cannabis law firm, shared: “It appears that many people are concerned when they realize that the very agency charged with enforcing the Controlled Substances Act , is also tasked with a possible rescheduling. “Cannabis.”

“The only confidence that the DEA will decide to reauthorize cannabis is based on precedent. The Congressional Research Service reported that it was not aware of any cases in which the DEA rejected a rescheduling recommendation from the FDA and HHS. While the DEA can and ultimately may decide not to reclassify cannabis, this would be an unprecedented step,” Cooper said.